6-4-18 >

CALDERDALE & HUDDERSFIELD NHS FOUNDATION TRUST A. ICEASK WAS AUTHORISATION AND RECORD OF AGREEMENT OF NAMED HEALTH PROFESSIONALS TO ADMINISTER MEDICINES UNDER: M.DAJIES

PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF LIDOCAINE (LIGNOCAINE) 1% INJECTION BY REGISTERED HEALTH PROFESSIONALS IN EMERGENCY DEPARTMENTS



J. 40UD

1. PGD AUTHORISATION

Position	Name	Signature	Date
Acting Clinical Director of Pharmacy	Fiona Smith	Mugh	23/3/18
Executive Director of Nursing	Brendan Brown	Junuan In	28/03/18
Medical Director	David Birkenhead	D Bring a	28/3/18
Chairman of Medicines Management Committee	Anu Rajgopal	Q-	29/3/18

Date of Patien	t Group Direction:	March 2018
----------------	--------------------	------------

If revision please tick box $\sqrt{\ }$

Valid Until: March 2020

Review Date: September 2019

Approved by the Trust Medicine Management Committee on: 2474 MAY 2018

PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF LIDOCAINE (LIGNOCAINE) 1% INJECTION BY REGISTERED HEALTH PROFESSIONALS IN EMERGENCY DEPARTMENTS

2. CLINICAL CONDITION

Relevant National and Local Guidelines/Information sources	Patients who require local anaesthesia prior to wound management, suturing, or incision and drainage. Licensed use
Description of Patients included in treatment	Any patient who requires local anaesthetic prior to interventions
Description of Patients excluded from treatment under the terms of this PGD	 Certain types of heart disease, particularly those affecting cardiac conduction Previous hypersensitivity to local anaesthetics Previous infection in the area around the injection. A history of renal or liver impairment Potentially serious drug Interactions
Action if excluded	Refer to doctor or Advanced Clinical Practitioner
Action if patient self excludes/declines	Refer to doctor or Advanced Clinical Practitioner

3. TREATMENT

Name, form and strength of medicine	Lidocaine (Lignocaine) 1% injection
Legal Status <i>GSL, P, POM</i>	POM
Dose	Incremental subcutaneous doses up to 3mg/kgs to a maximum 200mg. 1% solution contains 10mg/ml lidocaine. 2% solution contains 20mg/ml lidocaine.
Frequency of administration	Once Only
Method and route of administration	Subcutaneous
Supporting facilities required	Full resuscitation capacity available
Quantity to supply/administer	Sufficient to achieve local anaesthesia – NB maximum dose
Duration of treatment	Once only

PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF LIDOCAINE (LIGNOCAINE) 1% INJECTION BY REGISTERED HEALTH PROFESSIONALS IN EMERGENCY DEPARTMENTS

Potential side effects	 Allergic reactions ranging from rashes to severe (normally immediate) hypersensitivity reactions. Syncope (needle phobia) Sleepiness, dizziness, vertigo, blurred vision, mood changes, confusion, trembling, tingling, temperature fluctuation and stomach upset. (occasional occurrence normally only as a result of I/V administration) Convulsions, impaired consciousness, fall in blood pressure, abnormal heart rate and shock. (very occasional occurrence normally only as a result of I/V administration) 	
Advice to patient/carer	You should not receive this medicine if you have: Certain types of heart disease, particularly those affecting cardiac conduction Previous hypersensitivity to local anaesthetics Previous infection in the area around the injection. A history of renal or liver impairment Lidocaine can interact with some medicines. What medication are you taking?	
Managing & Reporting Adverse Events	 All suspected adverse drug reactions occurring after treatment following this PGD must be reported to a senior medical practitioner responsible for the area in which the direction is in use The healthcare professional administering/supplying from the PGD must also report the ADR using Trust incident reporting procedure All serious adverse drug reactions should be reported to the MHRA / CSM using the Yellow Card System. Yellow cards and guidance on its use are available at the back of the BNF or at www.yellowcard.gov.uk 	
Follow up	As required by clinical condition	
When to refer to doctor	Any reaction to medication	
Treatment record Specify method of recording supply/administration sufficient for audit trail	 Document in Electronic Patient Record in ED Prescription Name , dose, and frequency of drug Advice given, verbal or written Signed and dated 	

PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF LIDOCAINE (LIGNOCAINE) 1% INJECTION BY REGISTERED HEALTH PROFESSIONALS IN EMERGENCY DEPARTMENTS

4. STAFF

Professional Qualifications	Registered Nurse or Registered Paramedic Current NMC or HCPC Registration
Any Exceptions to above	Bank and Agency Staff
Specialist competencies, qualifications and experience	Trust PGD Training Programme (ED)
Continuing training & education	Update in line with clinical guidance

5. MANAGEMENT AND MONITORING

Records to be kept for Audit	STORAGE AND RETRIEVAL	
Purposes	 Pharmacy will retain the original signed version of the PGDs Adult – 8 years Children (under 18 years) As the requirement is until child is 25 years old or for eight years after child's death and PGDs are not child specific – this would be indefinitely (at least a minimum of 43 years) Division/Author is responsible for keeping the record/retrieval method of those authorised to work under a 	
Date of writing	PGD/signature sheet to comply with the above March 2018	
Name of manager holding record of names of those authorised to work under this PGD	Louise Croxall – Matron, ED	

PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF LIDOCAINE (LIGNOCAINE) 1% INJECTION BY REGISTERED HEALTH PROFESSIONALS IN EMERGENCY DEPARTMENTS

Names of all authors of PGD (to include a Dr or Dentist)	Print Name: Janet Youd
	Title: Emergency Nurse Consultant
	Signature: Janet Youd. Date: 2013118
	Print Name: Dr Mark Davies .
	Title: Emergency Medicine Consultant
	Signature: Date: 7(13)
Lead Pharmacist involved in preparation of PGD	Print Name: Łisā Hodgson
	Signature.
	Date: 2.3/.3/.18.
Approval of Clinical Director	Print Name: Mark Davies
	Signature:
	Date:

PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF LIDOCAINE (LIGNOCAINE) 1% INJECTION BY REGISTERED HEALTH PROFESSIONALS IN EMERGENCY DEPARTMENTS

This Patient Group Direction is to be read and agreed and this Authorisation and Record of Agreement signed by all Health Professionals who will administer and/or supply treatment using it. It is the responsibility of each professional to practice only within the bounds of their own competence

A copy of the Patient Group Direction and the original, signed Record of Agreement must be held together by the Ward/Departmental Manager/Community Team Leader.

'I confirm that I have read and understood the content of this Patient Group Direction and that I am willing to work under it within my Professional Code of Practice/Conduct.'

Name of Health Professional	Designation e.g. RGN	Signature of Health Professional	Signature of Ward/Departmental/Area Manager	Date